Private Equity Korea » Korea M&A

The largest Korean M&A deals 1H 2011

Brett Moffat — Thu, 28 Jul 2011 06:46:42 +0000

The ten largest Korean M&A deals in the first half of 2011 show diversification across industries, investment direction, and deal drivers.

The top three places on the list are taken up by pure domestic transactions, including the acquisitions of Hyundai E&C, Korea Express, and Daewoo E&C.

Seagate’s acquisition of Samsung Electronics’ HDD division and Mahindra & Mahindra’s acquisition of restructured automaker Ssangyong Motor are two inbound cross-border deals that made the list.

Two private equity deals are also on the list, the Mirae Asset PE consortium’s takeover of Acushnet and Vogo’s acquisition of an additional stake in Tong Yang Life Insurance.

Source: The Bell

Entekhab’s acquisition of Daewoo Electronics in jeopardy

Brett Moffat — Tue, 24 May 2011 12:21:33 +0000

The creditors of Daewoo Electronics, one of South Korea’s top three appliance makers, have failed to finalize the deal with selected preferred bidder, Iranian h0me appliance maker Entekhab, Korean media sources reported on Tuesday.

Entekhab which has paid 57.8 billion won in down payment of the 413.7 billion won purchase price has requested a 60 billion won discount of the final price.

The Iranian firm is requesting the discount due to complications with supply contracts with Daewoo Electronics’ current partners, including Bosh and Electrolux, along with claimed that it could not properly assess the value of Daewoo Electronics, as the creditors denied its request to extend the period for examining the company before the acquisition contract was signed.

The primary creditor, Woori Bank, is currently collecting the opinions of the other creditors on cutting the acquisition price but only have until the end of May to conclude the deal

As reported earlier, this is the fourth time that Daewoo Electronics creditors, including Korea Asset Management Corp. and Woori Bank, have tried to sell the company.

Courtesy of JoongAng Daily

In April last year creditors selected Entekhab as the preferred bidder, and signed the contract in November.

However the deadline for payments has been pushed back twice as Entekhab failed to make the date.

The creditors will need to seek an alternative method to sell Daewoo if they fail to reach an agreement with Entekhab. The most likely possibilities are to start negotiating with Electrolux – who was runner-up in the previous bid – or to hold a new auction from scratch.

Sources: JoongAng Daily, MK Business News

Mahindra & Mahindra concludes Ssangyong acquisition

Brett Moffat — Thu, 17 Feb 2011 00:15:50 +0000

Mahindra & Mahindra (M&M), the India-based automobile sector player, has concluded its acquisition of Ssangyong, the South Korea-based automobile company, reported The Times of India.

The newspaper cited Pawan Goenka, president, automotive and farm equipment division, M&M.

The deal was sealed by M&M on 9 and 10 February, when Ssangyong formally allotted it a 70% stake, the paper reported, and put the deal size at about USD 385m.

See here for all stories on the sale of Ssangyong.

Source: The Times of India

Hana Financial to issue shares to fund KEB acquisition South Korean Hana Financial Group announced yesterday it will issue...

Entekhab Industrial’s acquisition of Daewoo Electronics finalized soon

Brett Moffat — Wed, 25 Aug 2010 05:06:50 +0000

Creditors of Daewoo Electronics are likely to finalize the sale of the South Korean appliance maker to Entekhab Industrial as early as next week, reported the Korea Herald.

The report cited financial sector sources as saying that the creditors group is expected to hold a meeting to approve the sale next week. The deal value could be about KRW 100bn less than Entekhab’s initial offer of KRW 605bn (USD 508m), it added.

As reported, Woori Bank and other creditors selected Entekhab Industrial Group, the Iran-based electronic appliance maker, as the preferred bidder in the sale of Daewoo.

Source: Korea Herald (translated)

No related posts.

Korea’s first half M&A foreign direct investment totals $885mil

Brett Moffat — Wed, 07 Jul 2010 08:15:38 +0000

In the first half of 2010 M&A-type foreign direct investment (FDI) fell 43% as compared to the same period last year, according to the Ministry of Knowledge Economy’s latest figures.

M&A FDI amounted to $352 million for the second quarter, for a first half total of $885 million, down from $1.55 billion in the first half of 2009. The M&A FDI was split $453 million from the manufacturing sector, and $431 million from the service sector.

Major inbound-M&A transactions in the first half included Singapore’s Temasek Holdings investing $190 million in Celltrion, a biosimilar focused company, and GlaxoSmithKline’s $120 million investment in Dong-A Pharmaceuticals.

Total FDI into Korea also dropped on a year-on-year basis, falling 6.7% in the first half of 2010 to $4.33 billion, down from $4.64 billion a year ago. However, FDI inflows on a quarter-on-quarter basis increased 81% to $2.8 billion from $1.54 billion in the first quarter.

The ministry blamed the y-o-y decrease on the stronger value of the Korean won, which makes investing more expensive, and the lingering effects of the global financial crisis. The average value of the won was 1,154 against the U.S. dollar in the first half of this year against 1,351 won to the dollar in the first half of 2009.

A positive noted by the Ministry of Knowledge Economy’s report was an increase in the share of FDI received by the new growth industries, of biomedical, renewable energy, light-emitting diodes (LED) and software (31.3%, up from 15.8% last year).

In regards to the origin of FDI, the recent trend of inbound investment from emerging economies (so called south-south FDI), including China and the Middle East, surged 80.5% on-year to $1.9 billion,

whereas investments from advanced economies, including the U.S., Japan and Europe, fell 32.5% to $2.4 billion.

“Despite the decline of FDI in the first half, the country’s investment conditions are improving,” the ministry said, as reported in the JoongAng Daily.

“As the global economy recovers, there will be more flow of investment.”

Taking a look back at past FDI figures, Korea tends to attract more investment in the second half of the year, a trend which will need to continue if the country is going to reach its 2010 FDI target of $13 billion.

The full FDI report can be downloaded here (Korean). Or see here for the JoongAng Daily English-language article covering the announcement. And here for the post on the 2010.1Q results.

No related posts.

Global pharma eyeing Korean acquisitions as nation becomes test-bed

Brett Moffat — Mon, 31 May 2010 05:47:37 +0000

Two thousand and nine was a bumper year for global pharmaceutical M&A, with drug makers’ deals amounting to U$147.2 billion, including Pfizer’s U$68 billion deal for Wyeth and Merck’s U$41 billion deal with Schering-Plough, with most predicting M&A activity is set to continue throughout 2010 and beyond, buoyed in particular by emerging market deals.

Which was the case earlier this month, when GlaxoSmithKline (GSK) announced a strategic alliance with Korea’s Dong-A Pharmaceuticals Co., Ltd., acquiring a 9.9 percent minority equity shareholding in Dong-A for KRW 142.9bn (U$115 million).

It is “a significant opportunity for GSK to extend its commercial footprint and build operational scale in this fast growing Asian market,” said Christophe Weber, GSK’s senior vice president & regional director of Asia Pacific, in a press release regarding the alliance.

Novartis, another pharma giant, has pledged to invest U$20 million through its Novartis venture fund, to provide financial support for Korean small-sized bio companies with innovative ideas.

The fund has so far invested U$1 million each in, Neomics Inc., a local oncology bioscience startup, and PharmAbcine, a therapeutic antibody treatments provider.

Pfizer Korea, have also stated their will to seek more opportunities for partnerships in Korea as they try to develop treatments for Asia-prevalent diseases. Whilst earlier in the year it was rumored that Bayer was assessing acquisition targets in Korea, however, no deals have been announced so far.

Added to this, Novartis and Sanofi-Aventis are both participating in the Korea Trade-Investment Promotion Agency’s ‘Global Alliance Partnership Series’, an initiative created to facilitate R&D cooperation, investment, and strategic alliances between Korean companies, universities and research institutes, and leading global corporations.

Korea’s pharmaceutical industry has also caught the eye of financial investors, with Singaporean sovereign wealth fund Temasek Holdings acquiring a 10-per-cent stake in Celltrion, a biosmiliar company, for U$187.5 million, in April of this year.

One reason cited for this increased interest in Korea is the nation’s drug development infrastructure.

Korea is often cited as a test-bed for new mobile communication technologies, however due to strong clinical infrastructure the nation is now gaining recognition as a test-bed for new drugs, as global pharmaceutical companies target Asia.

According to Korea’s Ministry of Education, Science & Technology’s Biotechnology White Paper for 2007 and data compiled by the Korea Food and Drug Agency, the number of global clinical trials undertaken in Korea under the sponsorship of multinational companies surged from only 5 in the year 2000 to 216 in 2008, with an estimated 60,000 Korean patients enrolled in these clinical programs in 2008 and 2009.

“This sharp increase is a testament to the high degree of professionalism and efficiency at Korea’s leading hospitals, where most of the clinical trials are undertaken,” Friedrich Gause, Bayer Korea CEO stated at the ‘Pharma CEOs Round-table Meeting with the Ministry of Health and Welfare’, in Seoul, May 20, 2010, reported the Korea Herald.

Whilst in an interview with the JoongAng Daily in October last year, Guenter Reinke, CEO of Boehringer Ingelheim Korea Ltd (BIK) commented that “Korea has great potential as a market for clinical trials, particularly because of the country’s solid hospital infrastructure, ample research data and strong government support.”

In fact, Korea’s infrastructure for clinical trials is partly the result of the government’s conscious efforts to cultivate the health care industry.

“One key goal of the Health and Welfare Ministry’s R&D program is to make Korea the hub of clinical development in Northeast Asia,” Maeng Ho-young, the Ministry’s Director of Healthcare R&D, was quoted as saying at the Round-table meeting.

“We have been focusing R&D investment on beefing up infrastructure for advanced clinical trials because this is the best way to develop new drugs and medical devices. We hope the improved infrastructure for clinical trials will attract more multinational trials in Korea.” Maeng added.

The Korean government impetus seems already to be bearing fruit, with the world’s third largest drug maker, by sales, Novartis, planning to increase their number of clinical trials from 63 this year to 83 in 2011, according to Novartis Korea’s CEO Peter Jager.

This comes after Novartis announced last October that they will invest US$100 million in South Korea over the next five years to bolster research activities aimed at developing new drugs while increasing cooperation in the domestic bio industry.

“Korea has clear strengths in its excellent medical infrastructure, its world-class researchers and medical professionals, showing high expertise and passion to advance medical sciences in Korea.” Jager said in a statement at the time.

Sanofi-Aventis MOU signing ceremony - June 2009

And in June 2009, Sanofi-Aventis, the fourth-largest pharmaceutical company in the world, signed a memorandum of understanding to invest KRW 70 billion (U$56 million) in Korea’s medical R&D sector over the next five years.

Another major global player, Pfizer, currently conducting around 90 multinational clinical trials in Korea, across a range of therapeutic areas, is also looking to add to this number, according to a PharmAsia News report, citing, Pfizer Korea Medical Director Lee Won-Sik.

“In Korea, the Investigational New Drug review process is one to two months [30 business days] at the Korea Food and Drug Administration. And I have heard that it takes longer to complete the IND review process in other Asian countries,” Lee said, responding to questions why Pfizer aims to conduct more clinical trials in Korea rather than other Asian countries.

Global Pharmaceutical Companies’ Emerging Market Push

Korea’s R&D infrastructure is not the only thing attracting global pharma interest.

Slow growth in developed markets, combined with an increase in income levels, and the related lifestyle-related diseases, along with aging populations, in the Asia region, is prompting global pharmaceutical giants, such as GSK, Sanofi-Aventis, Pfizer, and Novartis to expand their business to emerging markets in Asia.

Taking a look at the situation in Korea, the percentage of people over the age of 65 is likely to surge from 11.0% in 2010 to 15.6% by 2020, and shoot up as high as 38.2% in 2050, as South Korea has one of the lowest birth rates among the OECD countries (1.19 children born per woman in 2008), according to a report released by the OECD on May 27, 2010.

According to the same OECD report, the nation’s per capita Gross Domestic Product (GDP) and Gross National Income (GNI) have been steadily rising, with the per capita GDP on a purchasing power parity basis (PPP) reaching U$27,658 in 2008.

These reasons prompted Peter Jager, president of Novartis Korea to state that Korea one of the key emerging pharmaceutical markets in the world, in an interview with a local news outlet.

(Source: Korea Times)

Long term Korea resident, Reinke, has witnessed firsthand the lifestyle changes in Korea, “I have been working in the Korean pharmaceutical industry for the past 12 years, seeing the lifestyle of Koreans change to a large extent. Such changes, including westernized eating styles, have brought to Korea an increase in chronic diseases such as diabetes and high blood pressure, like Europe.” Reinke told the local media in a recent interview.

And now that other nations in Asia start to follow Korea’s unhealthy lead, the region holds the key for the global pharmaceutical industry’s growth.

As well as offering, high-class infrastructure, another advantage of conducting clinical trials in Korea for Asia-focused drugs is genetics. Obviously, as being part of Asia, Koreans are a closer biological make-up to neighboring populations, but according to Gause, the key factor is body size, a crucial part of drug dosage testing. With Asian people in general less robust than Europeans.

Additionally, Korea represents a perfect test-bed for diseases more prevalent in Asia, than elsewhere, in particular stomach and liver cancer.

Stomach cancer (or gastric cancer) is the most common cancer in Korea, with a recent study by Korea’s National Cancer Center Research Institute pointing the finger at the nation’s salty diet for the high incidence, stemming from the high amount of pickled food consumed in Korea, such as the national dish – kimchi (fermented cabbage).

“As an R&D-based global pharmaceutical company, Pfizer has realized that it is critical to develop innovative drugs treating liver and stomach cancer, two cancer types more prevalent in Asians and, therefore, [Pfizer] has been leading investments and R&D efforts to provide innovative drugs and medicines in these areas,” Pfizer Korea’s Lee Won-Sik told PharmAsia News, in April 2010.

Pfizer and South Korea’s state-run Korea Research Institute for Bioscience and Biotechnology (KRIBB) expanded an earlier agreement May 18 to jointly develop drugs for liver and gastric cancer and to invest a total of KRW 300 billion (U$240 million) from 2008 to 2012.

Korea’s Pharmaceutical Industry

According to Invest KOREA the national investment promotion agency, the Korean pharmaceutical market (over-the-counter) has shown a 13.9% CAGR from 2006-08, and was valued as the 13th largest pharmaceutical market in the world, in 2008. With the CAGR of healthcare expenditure to GDP in Korea about twice higher (2.98%) than the OECD average (1.62%), and also, the percentage of drug expenditure in total healthcare expenditure (25.8%) is higher than the OECD average (17.6%).

Korean market size for over the counter (OTC) and ETC (Prescription) drugs - Source: Invest Korea

Realizing these factors, and the need to address the rising costs of present and future healthcare, the Korean government identified “Biopharmaceutical and medical equipment” as one of the future engines for economic growth. Creating the KRW 2 trillion (U$1.6 billion) “Bio-Medical Fund” to be used for R&D in order to help accelerate the launch of new drugs, along with tax breaks for companies researching new drugs.

Under the new plan, the rate of tax deductions will be expanded from 6 percent on R&D investments to 20 percent, one of the highest levels worldwide.

At last week’s round-table, the CEOs of foreign and local companies also offered advice to the Korean government on how it could improve the R&D environment further. With the attendants taking the opportunity to raise the issue of enhanced certainty in pricing and reimbursement to adequately reward the developers of drugs.

Citing the need for a predictable and transparent pricing process, in order to guarantee a return on the lengthy expensive investment required for drug development.

In efforts to address these problems Korea’s National Assembly recently passed a revised law to eliminate “kickbacks” and illegal rebate practices, which included stiffer penalties for infringement. The new law is set to come into force from November this year.

Jager and other CEOs also had concerns about the drug pricing policies, with Baek Young-ha, Deputy Director of the Pharmaceutical Benefits division, responding that the government would review existing price-lowering measures when the new drug-pricing system goes into effect in October.

In the second-half of 2010 and beyond, interest from global companies and investors in the Korean pharmaceutical market looks set to continue, as strong government support, high-class infrastructure, and emerging market drug gateway, make Korea a competitive investment destination.

For an opportunity to meet with Korea’s leading pharma & biotech companies see the upcoming event - Global Bio & Medical Forum, or for more information about acquisition opportunities in this growing sector, contact Invest KOREA on 82-2-3460-7536, or via email.

Story by Brett Moffat, Investment Partnership Support Team, Invest KOREA.

Sources:
Korea emerging as global drug trial hub – Korea Herald, May. 26, 2010
Korean Bio industry looks for transformation in 2010 – Bio Spectrum Asia, Jan. 18, 2010
Pfizer Will Seek Out More R&D Opportunities in Korea- BioPharma Today (PharmAsia News), Apr. 14, 2010
GSK extends presence in Asia with new strategic alliance in South Korea – GSK Website, May 11, 2010
New $1.7B fund aimed at bolstering drug R&D- JoongAng Daily, Feb. 08, 2010
Korea can excel in clinical trials- JoongAng Daily, Oct. 29, 2009
Pharma exec praises support for new drug research- JoongAng Daily, Mar. 09, 2010
OECD: S. Korea, One of Lowest Birth Rate Country - Maeil Business Newspaper, May. 28, 2010
Salty diet tied to stomach cancer in Korean study – Reuters, Mar. 24, 2010
Investment Opportunity – Biotech & Pharmaceutical Industry – Invest KOREA, Sep. 2009
Novartis – Knowledge Investor – Invest KOREA Journal, Jan. 2009
Pharmaceutical giant Novartis to invest US$100 Mil in S. Korea – Novartis press release, Oct. 2009
Pharma M&A: 10 years, 1,345 deals, $694B- Fierce Pharma Website, Mar. 26, 2010

No related posts.

Local interest in M&A increasing, yet negative perceptions remain

Brett Moffat — Wed, 12 May 2010 09:37:16 +0000

The interest in pursuing M&A as a growth strategy is increasing amongst Korean companies, as many seek new growth opportunities.

A survey of Korean executives conducted by Samsung Economic Research Institute (SERI) found 68% of 288 respondents planning M&As, however, up to now, M&A activity has not matched the recent interest.

Korea’s announced M&A volume is quite small in proportion to its economic size, with Korea ranked 32nd in the number of announced M&A deals and 38th in the number of M&As abroad, as of 2008, according to Korea Economic Research Institute.

According to the SERI survey results, the main reason that Korean companies have sealed fewer M&A deals is due to a lack of deal experience, conservative corporate culture, and management’s defensive attitude toward M&A deals rather than external factors.

Korean business executives’ negative perception, and defensive attitude towards M&As stems from bad memories of government-led restructuring M&As, hostile M&A attempts by hedge funds, and financial troubles after an acquisition (so called “winners curse”).

The full report “Lessons from Global Companies’ M&As” can be downloaded free of charge from the SERI Website, after registration.

(Source: SERI)

No related posts.

Shinil Construction up for sale

Brett Moffat — Fri, 23 Apr 2010 01:23:21 +0000

Ernst & Young Han Young, the financial advisor for the sale of Shinil Construction, officially announced the sale of the unlisted South Korean construction company.

According to the press release, the sale will be carried out via a public competitive bidding.

The advisor is open to receiving letters of intent from potential buyers up to 17:00 (local time), 13 May 2010, with due diligence scheduled between 17 May and 31 May.

(Source: Shinil Construction)

More From privateequitykorea

No related posts.

Ssangyong Motor draws interest from SM Group

Brett Moffat — Tue, 20 Apr 2010 01:51:31 +0000

SM Group, a South Korean conglomerate that has several listed subsidiaries under its wing, has showed interest in buying Ssangyong Motor, reported the Seoul Economic Daily.

Ssangyong Motor, the listed South Korean auto maker, entered into court receivership in 2008 and currently is involved in a debt workout program.

The report cited SM Group president, Woo Oh-Hyun, who said in an interview with the paper that he believes the electric vehicle industry could be a good market for Ssangyong to grow into.

Woo said if his group, which now develops parts and batteries for electric vehicles, acquires Ssangyong, it could generate a great synergy.

SM Group, which has 14 subsidiaries in the construction and chemical and textile industries, recorded total revenues of KRW 1.2tn (USD 1.07bn) last year.

Ssangyong Motor has a market cap of KRW 466bn (USD 416m).

See here for all posts on the sale of Ssangyong Motor.

(Source: Seoul Economic Daily)

No related posts.

Entekhab selected as preferred bidder for Daewoo Electronics

Brett Moffat — Thu, 15 Apr 2010 00:47:47 +0000

Woori Bank has chosen Iran-based Entekhab Industrial Group as a preferred bidder in the sale of Daewoo Electronics, the unlisted South Korean household electronic appliance maker, according to an Woori Bank press release.

The Woori Bank-led creditors group will soon sign a memorandum of understanding with Entekhab Industrial Group and finalize the deal by the end of July at the earliest, the release said.

Sweden-based Electrolux AB will remain in the sale as a secondary priority bidder, it said.

An Edaily news report, stated that Entekhab’s offer price was around the KRW 600bn (U$536m) mark.

For more information and links to previous stories regarding the sale of Daewoo Electronics, see the previous post “Electrolux and Entekhab Industrial make offers for Daewoo Electronics“.

(Sources: Woori Bank, Edaily)

More From privateequitykorea

No related posts.